Global Clinical Trials Market Research Report 2024: $83.16 Billion Market by 2030

Global clinical trial market

DUBLIN, April 19, 2024 (GLOBE NEWSWIRE) — “Clinical Trials Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insights, Inflation Impact, Company Analysis” report added Ta. ResearchAndMarkets.com Recruitment.

The global clinical trials market is projected to reach approximately USD 83.16 billion by 2030 from USD 55.2 billion in 2023, growing at a CAGR of 6.03% during 2024-2030.

Today, the clinical trials industry is evolving with technological advancements, regulatory streamlining, and patient-centric approaches. AI, machine learning, and blockchain will transform clinical trials. These will make clinical trials more efficient and cost-effective while increasing comprehensiveness and diversity. Precision medicine and biomarker-driven clinical trials enable personalized treatment for each patient.

The increasing burden of diseases requires more advanced and effective therapeutics, contributing to market growth. For example, according to the IDF Atlas, 536.6 million people between the ages of 20 and 79 worldwide have diabetes, and by 2045 it is expected to reach 783.7 million. Such excessive disease burden also drives market expansion. Additionally, a major trend is for manufacturers to outsource clinical research activities. Pharmaceutical and biotechnology companies are reinventing their drug development facility businesses by outsourcing R&D projects.

Research and development service providers range from a small number of facilities offering limited clinical trial facilities to a wide range of facilities including study design, preclinical evaluation, clinical trial management and planning, autonomous safety data audits, and biostatistical analysis. It has grown into a large conglomerate that provides Contract Research Organizations (CROs) began by providing preclinical and clinical testing facilities. However, we are currently working on project management.

The North America region is expected to contribute significantly to the market growth during the study period due to factors such as high R&D expenses in the pharmaceutical industry, presence of established players, strong regulatory framework, and increasing prevalence of diseases. . With significant contributions from the United States.

Strong foothold in the pharmaceutical industry, continued advances in clinical trial research, increased spending on research and development (R&D), growth in the biosimilar and generic markets, and increased availability of preclinical, clinical, and laboratory testing services from pharmaceutical and biopharmaceuticals. The growing trend of outsourcing Companies in the region are all contributing to this outcome. For example, the National Cancer Institute (NCI) conducts clinical trials in the United States under the regulations of the Food and Drug Administration (FDA). This federal company funds most cancer clinical tests in the United States.

Phase 3 trials hold the largest market share in global clinical trials

The global clinical trials market is divided into phases: Phase 1, Phase 2, Phase 3, and Phase 4. The Phase III section is expected to lead the industry. Clinical trial statistics indicate market growth due to an increase in Phase III trials involving a large number of subjects. The average cost of a single phase III trial is over $19 million. Phase III also requires more patients and a longer treatment period.

story continues

On the other hand, the Phase II section is expected to see a significant increase during the analysis period. Phase II plays an important role, especially in oncology-related research. The FDA estimates that approximately 33.0% of investigational drugs are typically in Phase II trials. Additionally, numerous therapeutics and vaccines currently in Phase II are being adapted for oncology treatment, boosting the market growth.

According to forecasts, oncology is expected to be the leading indication segment of the clinical trials market

By indication, the global clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS conditions, diabetes, obesity, cardiovascular, and others. The oncology sector held the most extensive clinical trials market share. This large share can be attributed to the increasing prevalence of cancer internationally and the large number of oncology clinical trials being conducted around the world.

For example, according to clinicaltrials.gov, for cancer drugs, there are approximately 106 early phase I intervention trials underway, 2478 phase I intervention trials conducted, and 4219 phase II intervention trials. was conducted, resulting in 2031 phase III intervention trials. Clinical trials are ongoing, with 585 Phase IV intervention trials conducted in 2022.

Intervention Research is the undisputed global clinical trial market leader

The global clinical trials market is segmented by research material into interventional, observational, and expanded access. Interventional research is projected to dominate the clinical trials market. The requirement for clinical trials to improve diagnostic tests and vaccines for viral diseases such as SARS-CoV-2 has exponentially increased the demand for clinical trials. Therefore, the high incidence of novel viral diseases and continuous technological improvements in clinical trials are major reasons for the high revenue share of intervention studies.

Key attributes:

Company analysis:

• Icon Co., Ltd.

• Wuxi AppTec

• SGS SA

• Syneos Health

• PRA Health Science Co., Ltd.

• Pfizer Japan Inc

• IQVIA

• Sanofi (France)

• Medpace

Phase – The global clinical trials market is segmented into four aspects:

• Phase 1

• Phase 2

• Phase 3

• phase 4

Indications – The global clinical trials market is categorized from eight perspectives:

• autoimmune/inflammation

• pain management

• oncology

• Central nervous system condition

• Diabetes

• obesity

• cardiovascular

• others

Research Materials – The global clinical trials market is categorized from three perspectives:

• intrusive

• observational

• expanded access

Breakdown of the global clinical trials market from the perspective of 25 countries:

• North America

• America

• Canada

• Europe

• France

• Germany

• Italy

• Spain

• England

• Belgium

• Netherlands

• turkey

• Asia Pacific

• China

• Japan

• India

• South Korea

• Thailand

• Malaysia

• Indonesia

• Australia

• new zealand

• latin america

• Brazil

• Mexico

• Argentina

• middle east and africa

• Saudi Arabia

• United Arab Emirates

• South Africa

For more information on this report, please visit https://www.researchandmarkets.com/r/ckxhpt.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900